Opendata, web and dolomites


Development of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types.

Total Cost €


EC-Contrib. €






 SYST-iMYC project word cloud

Explore the words cloud of the SYST-iMYC project. It provides you a very rough idea of what is the project "SYST-iMYC" about.

therapies    tissues    found    drug    treatment    tumorigenic    annually    clinically    ing    lymphoma    continue    variant    contributes    cellular    suppression    catastrophic    transferred    cancer    clinical    indications    erc    cog    patients    purified    unexpected    vitro    company    market    potentially    establishing    reaching    peak    commercial    mouse    revenue    direct    passing    current    breast    showed    2013    patent    industrial    spin    lung    inhibit    dr    ready    normal       deg    human    redundant    class    reversible    soucek    melanoma    poc    functions    models    wanted    brain    limited    forecasted    612    de    innovative    milestones    commercialization    anti    cell    penetrating    types    resistance    active    mutant    inhibition    compensated    enter    unfeasible    off    tumorigenesis    protected    designed    local    immune    inhibitor    intranasal    risk    trials    probability    causing    emergence    dogma    cells    critically    vivo    polypeptide    omomyc    feasibility    discovered    617473    systemic    dramatic    therapeutic    thanks    cancers    myc    data    first    multiple    estimations    tumors   

Project "SYST-iMYC" data sheet

The following table provides information about the project.


Organization address
address: CALLE NAZARET 115-117
postcode: 8035

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 148˙875 €
 EC max contribution 148˙875 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2019-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Current cancer therapies target redundant cellular functions often compensated for by cancer cells, resulting in resistance to treatment. Here we propose an innovative approach to inhibit Myc, a non-redundant and “most-wanted” therapeutic target for human cancer. Targeting Myc has long been considered unfeasible because of the potentially catastrophic side effects in normal tissues. Against this dogma, we showed that Myc inhibition by Omomyc, a Myc mutant designed by Dr. Soucek, has a dramatic therapeutic impact in multiple mouse models of cancer, while causing only limited and reversible side effects. Critically, there is no emergence of resistance. Thanks to the ERC-2013-CoG n° 617473, we discovered the unexpected cell-penetrating properties of the purified Omomyc polypeptide. Moreover, we found that it is anti-tumorigenic after local (intranasal) delivery to mouse models of lung and brain tumors, and could therefore become the first clinically-viable direct Myc inhibitor. With this ERC PoC, we propose to develop a new drug based on an Omomyc variant that enables systemic treatment of several cancer types including lymphoma, breast, and melanoma. In all these cancers Myc contributes to multiple aspects of tumorigenesis including immune suppression. At the end of this project we will have a patent protected therapeutic polypeptide active in vitro and in vivo and ready to enter clinical trials Phase I/II in patients and to continue its commercialization. The forecasted peak revenue for such first-in-class drug in those indications reaches 2.612 M€ annually. With this ERC PoC project we will achieve essential milestones to develop this innovative therapeutic polypeptide by establishing the feasibility, including a commercial data package and cost estimations for the industrial production. Passing these milestones will de-risk the product and increase its value and probability of reaching the market by making it ready to be transferred to a spin-off company.


year authors and title journal last update
List of publications.
2019 Mireia Pesarrodona, Toni Jauset, Zamira V. Díaz‐Riascos, Alejandro Sánchez‐Chardi, Marie‐Eve Beaulieu, Joaquin Seras‐Franzoso, Laura Sánchez‐García, Ricardo Baltà‐Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz, Laura Soucek, Antonio Villaverde, Ibane Abasolo, Esther Vázquez
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies
published pages: 1900849, ISSN: 2198-3844, DOI: 10.1002/advs.201900849
Advanced Science 6/18 2020-03-05
2019 S. Ramón y Cajal, P. Sancho, L. Soucek, H. Peinado, M. Abad, M. Valiente, A. Efeyan, J. Pardo, V. Quesada, J. Jimeno, P. M. Duque, A. Antón, I. Varela, A. J. Schuhmacher
A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas
published pages: , ISSN: 1699-048X, DOI: 10.1007/s12094-019-02199-4
Clinical and Translational Oncology 2020-02-28
2018 Sílvia Casacuberta-Serra, Laura Soucek
Myc and Ras, the Bonnie and Clyde of immune evasion
published pages: S457-S459, ISSN: 2218-676X, DOI: 10.21037/tcr.2018.03.09
Translational Cancer Research 7/S4 2020-02-28
2019 Marie-Eve Beaulieu, Toni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, Peter Rahl, Loïka Maltais, Mariano F. Zacarias-Fluck, Sílvia Casacuberta-Serra, Erika Serrano del Pozo, Christopher Fiore, Laia Foradada, Virginia Castillo Cano, Meritxell Sánchez-Hervás, Matthew Guenther, Eduardo Romero Sanz, Marta Oteo, Cynthia Tremblay, Génesis Martín, Danny Letourneau, Martin Montagne, Migu
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
published pages: eaar5012, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aar5012
Science Translational Medicine 11/484 2020-02-28
2019 Jonathan Whitfield, Laura Soucek
Editorial overview: Peptides in cancer
published pages: iii-v, ISSN: 1471-4892, DOI: 10.1016/j.coph.2019.06.001
Current Opinion in Pharmacology 47 2020-02-28
2019 Marie-Eve Beaulieu, Laura Soucek
Finding MYCure
published pages: e1618178, ISSN: 2372-3556, DOI: 10.1080/23723556.2019.1618178
Molecular & Cellular Oncology 6/5 2020-02-28

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYST-IMYC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYST-IMYC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

HBPTC (2019)

Hydrogen Bonding Phase Transfer Catalysis

Read More  

HOLI (2019)

Deep Learning for Holistic Inference

Read More